Add To Watchlist
Share URL
About The Company
Description
Nipro Corporation, together with its subsidiaries, engages in the medical devices, pharmaceuticals, and pharma packaging businesses.
Read More
Overview
Value
88
Growth
33
Health
45
Management
50
Analyst Opinion
71
Total
57
All Scores Out Of 100
Best Features
- Has a history of share buybacks
- Price-to-earnings ratio of 13.6 is lower than the market average (19.6x)
- Has a margin-of-safety above fair value
- Liked by analysts
- Low preportion of income is paid as dividend
Risk Factors
- Earnings have declined recently
- Has a high level of debt
- Poor earnings and cashflow growth
- Very undervalued
Market Peers
8086.T
Key Figures
PE Ratio (TTM)
13.56
Margin Of Safety (DCF)
338.54%
Revenue Growth (5 Year Average)
7.84%
Ratings Consensus
Buy
Share Buybacks
0.48%
Dividend Yeild (TTM)
1.81%
Valuation
Value Score
88
- ✔ Price-to-earnings ratio of 13.6 is lower than the market average (19.6x)
- ✔ Free-cashflow-yeild of 12.96% is better than the market average (4.7%)
- ✔ Margin-of-safety of 338.54% is better than the market average (17.95%)
- ✔ Estimated intrinsic-value of 4.52 Thousand JPY is higher than current price ( 1.03 Thousand JPY)
Desired Margin Of Safety
0%
▼
Tip: Set your desired Margin Of Safety
Free Cash Flow Type
Annual Cashflow Growth
0%
Discount Rate
0%
Buy Target: < 4731.4 JPY ✔
Current Price: 1031 JPY
How Does This Work?
Show Advanced Options
This calculator helps investors estimate the Intrinsic Value of a company based on the current value of future cash flows. To use the tool, simply input a desired Margin Of Safety, which is an additional discount applied to the present value of the expected future cash flows. The tool calculates the present value using a discount rate that reflects the risk and time value of money, and provides an estimated target price for the company based on the selected margin of safety. The calculator defaults to using 5 Year Free Cash Flow Growth % and a discount rate based on the US 10-year treasury bond coupon rate. Use our performance analyser to get a feel the impact this has on longterm investment returns and discover a margin of safety you are comfortable with. This can be a useful tool for investors looking to make informed decisions about whether to buy or sell shares of a particular company.
Price/Earnings
13.56x
Free Cashflow Yeild
12.96%
PE/Earnings Growth
N/A
Price/Book
0.71x
Growth
Growth Score
33
- ✔ Revenue growth has improved this yeara
- ✘ 5 Year Average Revenue growth of 7.84% is lower than the market average (10.97%)
- ✘ 5 Year Average Earnings growth of 3.56% is lower than the market average (14.48%)
- ✘ Earnings growth has slowed this year
- ✘ 5 Year Average Free Cashflow growth of 3.21% is lower than the market average (12.35%)
- ✘ Free Cashflow growth has slowed this year
Revenue Growth
7.84%
Earnings Growth
3.56%
Cashflow Growth
3.21%
Health
Health Score
45
Altman Z Score
1.03
Piostroski Score
6.00
Debt/Equity
3.05x
Current Assets/Liabilities
1.40x
Free Cashflow/Total Debt
0.12x
Debt/Capital
1.29x
Dividend
Secure Dividend Score
53
- ✔ Dividend is likely safe
- ✔ Long term dividend payout ratio of 23.33% is considered good
- ✔ Payout ratio (TTM) of 24.49% is lower than the average (40%)
- ✔ Dividend growth has been accelerating recently
- ✘ Dividend yeild of 1.81% is less than the market average (1.85%)
- ✘ Dividends have been declining over the last 5 years
- ✘ Spending a higher percentage of their income on dividends than last 5 years
Dividend Yeild
1.81%
Dividend Growth
25.05%
Payout Ratio (Earnings)
24.49%
Payout Ratio (Cashflow)
13.94%
Management
Management Score
50
Average Buybacks/Dilution
0.48%
Recent Buybacks/Dilution
-0.00%
5 Year Price Volitility
12.82%
Return On Assets
1.45%
Return On Capital Employed
9.51%
Return On Equity
7.26%
Return On Free Cashflow
20.36%
Return On Investments
29.89%
Analysts
Analyst Opinion
71
- ✔ Ratings consensus is Buy
SEC Filings
Find yearly (10-K), quaterly (10-Q) and disclosure (8-K) report here, on the Securities and Exchange Commission's EDGAR database. If reading through reports isn't your cup of tea, don't worry. We've made it easy for you by summarizing all the important bits.
Other Information
Company Name
Nipro Corporation
Currency
JPY
Beta
0.312671
Vol Avg
398378
Ceo
Mr. Yoshihiko Sano
Cik
Cusip
Exchange
Tokyo
Full Time Employees
36259
Industry
Medical Instruments & Supplies
Sector
Healthcare
Ipo Date
2001-01-01
Address
3-9-3 Honjo-nishi
City
Osaka
State
Country
JP
Zip
531-8510
Phone
81 6 6372 2331
All financial data provided by FMP